Establishment of lung cancer patient-derived xenograft models and primary cell lines for lung cancer study

被引:19
|
作者
Jiang, Yanan [1 ,2 ]
Zhao, Jimin [1 ,2 ]
Zhang, Yi [3 ]
Li, Ke [1 ]
Li, Tiepeng [5 ]
Chen, Xinhuan [1 ,2 ]
Zhao, Simin [1 ]
Zhao, Song [3 ]
Liu, Kangdong [1 ,2 ,4 ]
Dong, Ziming [1 ,2 ]
机构
[1] Zhengzhou Univ, Sch Basic Med Sci, Dept Pathophysiol, Zhengzhou 450001, Henan, Peoples R China
[2] Henan Prov Cooperat Innovat Ctr Canc Chemoprevent, Zhengzhou 450001, Henan, Peoples R China
[3] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou 450052, Henan, Peoples R China
[4] China US Henan Hormel Canc Inst, Zhengzhou 450008, Henan, Peoples R China
[5] Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou 450008, Henan, Peoples R China
关键词
Lung cancer; Patient-derived xenograft; Signal pathway; Primary cell culture; IN-VIVO MODELS; MUTATIONS; EVOLUTION; THERAPY; PATHWAY; EGFR;
D O I
10.1186/s12967-018-1516-5
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: The overall 5-year survival rate of lung cancer is about 15% even with therapeutic drugs like tyrosine kinase inhibitors. Ideal models are urgently needed for exploring mechanisms and finding new drugs. Patient-derived xenografts (PDX) models and primary cells are both used to screen therapeutic regimens for cancer. However, PDX models and primary cells from the same patient are difficult to establish. Their consistency to the original tumor tissue is not well studied. Methods: 31 lung cancer patient tissues were procured to establish the lung cancer PDX models and primary cell lines. Tumor growth measurements, histological and immunohistochemistry analysis, Western blotting, EGFR and K-RAS mutation detection and gefitinib sensitive assay were performed to evaluate the characteristic of established PDX models. Immunofluorescence analysis, anchorage-independent cell growth, Western blotting and gefitinib sensitive assay were performed to assay the characteristic of established primary cell lines. The whole-exome sequencing was used to compare the characteristic of the patient's tumor tissue, established PDX and primary cell line. Results: Twenty-one lung cancer PDX models (67.74%, 21/31) and ten primary cell lines (32.25%, 10/31) were established from patients' tumor tissues. The histology and pathological immunohistochemistry of PDX xenografts are consistent with the patients' tumor samples. Various signal pathways were activated in different PDX models (n = 5) and primary cell lines (n = 2). EGFR mutation PDX model and primary cell line (LG1) were sensitive to gefitinib treatment. The expression of CK8/18, TTF1 and NapsinA in LG1 and LG50 primary cells were also positive. And the activated signal pathways were activated in LG1 and LG50 primary cell lines. Furthermore, the gene mutation in PDX tumor tissues and primary cell line (LG50) was consistent with the mutation in LG50 patient's tumor tissues. Conclusion: These data suggested that established lung cancer PDX models and primary cell lines reserved mostly molecular characteristics of primary lung cancer and could provide a new tool to further understand the mechanisms and explore new therapeutic strategies.
引用
收藏
页数:18
相关论文
共 50 条
  • [21] Patient-Derived Xenograft Models of Non-Small Cell Lung Cancer and Their Potential Utility in Personalized Medicine
    Morgan, Katherine M.
    Riedlinger, Gregory M.
    Rosenfeld, Jeffrey
    Ganesan, Shridar
    Pine, Sharon R.
    [J]. FRONTIERS IN ONCOLOGY, 2017, 7
  • [22] Patient-derived xenograft models in hepatopancreatobiliary cancer
    Binhua Pan
    Xuyong Wei
    Xiao Xu
    [J]. Cancer Cell International, 22
  • [23] Patient-Derived Tumor Xenograft Models: Toward the Establishment of Precision Cancer Medicine
    Goto, Taichiro
    [J]. JOURNAL OF PERSONALIZED MEDICINE, 2020, 10 (03): : 1 - 14
  • [24] Patient-derived xenograft models in hepatopancreatobiliary cancer
    Pan, Binhua
    Wei, Xuyong
    Xu, Xiao
    [J]. CANCER CELL INTERNATIONAL, 2022, 22 (01)
  • [25] Establishment of Lung Cancer Xenograft Models Derived from Bronchoscopy Biopsy and Investigating Mechanism of Refractory Small Cell Lung Cancer
    Wang, Jie
    Fu, Shuai
    Zhao, Jun
    An, Tongtong
    Bai, Hua
    Duan, Jianchun
    Wang, Zhijie
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S222 - S222
  • [26] Collection of lung cancer patient-derived xenograft (PDX) models to evaluate precision therapeutic strategies
    Molina-Pinelo, Sonia
    Melendez, Ricardo
    Suarez, Rocio
    Garcia, Laura
    Ojeda, Laura
    Moreno, Nicolas
    Guijarro, Maria V.
    Paz-Ares, Luis
    Ferrer, Irene
    [J]. CANCER RESEARCH, 2017, 77
  • [27] Establishment and Characterization of Patient-Derived Xenograft Model of Non-Small-Cell Lung Cancer Derived from Malignant Pleural Effusions
    Liao, Hong
    Zhou, Shixin
    Chen, Si
    Li, Jun
    Zhang, Zongqi
    Meng, Ling
    Liu, Qiliang
    Wu, Yuan
    He, Yuanqiao
    Li, Ming
    [J]. CANCER MANAGEMENT AND RESEARCH, 2023, 15 : 165 - 174
  • [28] Establishment of patient-derived tumor spheroids for non-small cell lung cancer
    Zhang, Zengli
    Wang, Huiqian
    Deng, Qifeng
    Xing, Yufei
    Xu, Zhonghua
    Lug, Chun
    Luo, Dongdong
    Xu, Longjiang
    Xia, Wei
    Zhou, Caicun
    Shi, Minhua
    [J]. PLOS ONE, 2018, 13 (03):
  • [29] The Use of Patient-Derived Xenograft (PDX) Models to Predict Patient Response in Non-Small Cell Lung Cancer (NSCLC)
    Isler, J.
    Katz, A.
    Sorogin, A.
    Scoppetuolo, M.
    Nechushtan, H.
    Pass, H.
    Davies, A.
    Paz, K.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S42 - S43
  • [30] Establishment of Patient-Derived Non-Small Cell Lung Cancer Xenografts as Models for the Identification of Predictive Biomarkers
    Fichtner, Iduna
    Rolff, Jana
    Soong, Richie
    Hoffmann, Jens
    Hammer, Stefanie
    Sommer, Anette
    Becker, Michael
    Merk, Johannes
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (20) : 6456 - 6468